RashnaMadanMD
Pathology • Kansas City, KSCytopathology, Anatomic Pathology, Clinical Pathology
Assistant Professor, Pathology and Laboratory Medicine, University Kansas School of Medicine
Are you Dr. Madan?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 23 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4000 Cambridge St
Kansas City, KS 66160Phone+1 913-588-1227Fax+1 913-588-7073- Is this information wrong?
Summary
- Dr. Rashna Madan, MD is a board certified pathologist in Kansas City, Kansas. She is currently licensed to practice medicine in Kansas and Connecticut. She is affiliated with The University of Kansas Hospital and is an Assistant Professor at University Kansas School of Medicine.
Education & Training
Montefiore Medical Center/Albert Einstein College of MedicineResidency, Pathology-Anatomic and Clinical, 2006 - 2007
Memorial Sloan Kettering Cancer Center Oncologic PathologyFellowship, Selective Pathology, 2005 - 2006- Montefiore Medical Center/Albert Einstein College of MedicineResidency, Pathology-Anatomic and Clinical, 2001 - 2005
Kasturba Medical College ManipalClass of 1997
Certifications & Licensure
KS State Medical License 2007 - 2024
CT State Medical License 2005 - 2008- American Board of Pathology Anatomic Pathology & Clinical Pathology
- American Board of Pathology Cytopathology
Publications & Presentations
PubMed
- QIM24-193: Development and Pilot Testing of a Comprehensive Set of Measures for Organizational Assessment of NCCN Guideline Recommended Genomic Testing.Shellie Ellis, Aaron Katz, Chao Huang, Samuel Boyd, Carolyn Caine, Whitney Onasch, Daniel Farrell, Jeffrey Thompson, Wei Zhang, Zseraldina Ferenczi, Andrew K Godwin, J...> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
- Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA ...Anwaar Saeed, Robin Park, Harsh Pathak, Ayah Nedal Al-Bzour, Junqiang Dai, Milind Phadnis, Raed Al-Rajabi, Anup Kasi, Joaquina Baranda, Weijing Sun, Stephen Williamson...> ;Nature Communications. 2024 Feb 20
- 4 citationsClinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.Priyanka Sharma, Shane R Stecklein, Rachel Yoder, Joshua M Staley, Kelsey Schwensen, Anne O'Dea, Lauren Nye, Deepti Satelli, Gregory Crane, Rashna Madan, Maura F O'Nei...> ;JAMA Oncology. 2024 Feb 1
- Join now to see all
Press Mentions
Targeted Inhibition of Histone Deacetylase Leads to Suppression of Ewing Sarcoma Tumor Growth Through an Unappreciated EWS-FLI1/HDAC3/HSP90 Signaling AxisApril 25th, 2019
Hospital Affiliations
The University of Kansas HospitalKansas City, Kansas
